Suppr超能文献

静脉注射维拉帕米对接受慢性普萘洛尔治疗患者的血流动力学影响。

The hemodynamic effects of intravenous verapamil in patients on chronic propranolol therapy.

作者信息

Reddy P S, Uretsky B F, Steinfeld M

出版信息

Am Heart J. 1984 Jan;107(1):97-101. doi: 10.1016/0002-8703(84)90140-6.

Abstract

Concern exists regarding the negative inotropic and chronotropic effects of verapamil given to patients receiving chronic propranolol therapy. In order to evaluate the safety of combined therapy, the hemodynamic effects of verapamil were investigated in a group of 19 patients on chronic propranolol therapy undergoing cardiac catheterization. Hemodynamic measurements and left ventriculography were performed prior to and 30 minutes after initiation of intravenous administration of verapamil. Verapamil doses varied from 0.025 mg/kg to 0.1 mg/kg intravenous bolus injection followed by an infusion of 0.005 mg/kg/min. Following verapamil administration, systolic, diastolic, and arterial mean pressures and systemic vascular resistance decreased significantly. There was no significant change in left ventricular end-diastolic pressure, mean pulmonary capillary wedge pressure, cardiac index, arteriovenous oxygen difference, heart rate, mean velocity of circumferential fiber shortening (VCF), end-diastolic volume index, end-systolic volume index, stroke volume index, and ejection fraction (EF). Stroke work index decreased significantly. Lack of improvement in cardiac index, VCF, and EF and decrease in stroke work index in spite of constant filling pressure and decreased afterload suggest the additive negative inotropic action of verapamil. The depressant action of propranolol itself was not determined by this study. In spite of the negative inotropic effect of verapamil, it can be administered acutely to patients who have been on propranolol therapy with relative safety if the propranolol has not already produced severe left ventricular dysfunction, relative hypotension, bradyarrhythmia, or conduction abnormalities.

摘要

对于接受慢性普萘洛尔治疗的患者给予维拉帕米时,其负性肌力和变时性作用令人担忧。为了评估联合治疗的安全性,在一组接受慢性普萘洛尔治疗且正在接受心导管检查的19例患者中研究了维拉帕米的血流动力学效应。在静脉注射维拉帕米开始前及开始后30分钟进行血流动力学测量和左心室造影。维拉帕米剂量从0.025mg/kg至0.1mg/kg静脉推注,随后以0.005mg/kg/min的速度输注。给予维拉帕米后,收缩压、舒张压、动脉平均压和全身血管阻力显著降低。左心室舒张末期压力、平均肺毛细血管楔压、心脏指数、动静脉氧差、心率、圆周纤维缩短平均速度(VCF)、舒张末期容积指数、收缩末期容积指数、每搏量指数和射血分数(EF)均无显著变化。每搏功指数显著降低。尽管充盈压恒定且后负荷降低,但心脏指数、VCF和EF未改善且每搏功指数降低,提示维拉帕米具有相加的负性肌力作用。本研究未确定普萘洛尔本身的抑制作用。尽管维拉帕米具有负性肌力作用,但如果普萘洛尔尚未引起严重的左心室功能障碍、相对性低血压、缓慢性心律失常或传导异常,则可相对安全地急性给予正在接受普萘洛尔治疗的患者。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验